Accessibility: Skip TopNav
Figure 5a
Soquelitinib Treatment Leads to Increase in Persistent Tregs (CD4+, Foxp3+, CD25Hi ) measured by flow cytometry.
Format
JPEG
Source
Corvus Pharmaceuticals, Inc.
Downloads
Original
Large
Medium
Small